Literature DB >> 1965845

Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells.

R H Kenyon1, R M Condie, P B Jahrling, C J Peters.   

Abstract

Antibody-containing plasma from patients recovered from Argentine hemorrhagic fever (AHF) is of proven value in treatment of the acute disease, but the possibility of transmitting blood-borne organisms such as HIV and hepatitis virus detracts from this approach. Purified human immune plasma fractions IgG1,2,4, IgG1,2,3,4 and F(ab')2 neutralized Junin virus in vitro. IgG1,2,3,4 and IgG1,2,4 lysed (in the presence of complement) cells infected with Junin virus, and protected infected guinea pigs from AHF. However, large quantities of the immune F(ab')2 fraction from the same plasma pool failed to protect guinea pigs from death, to increase the mean time to death, and to diminish virus load in target organs of infected guinea pigs. This suggests that elimination of infected cells rather than virus neutralization may play a critical role in protection against Junin virus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965845     DOI: 10.1016/0882-4010(90)90010-n

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  10 in total

1.  Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.

Authors:  Emily K Mantlo; Junki Maruyama; John T Manning; Timothy G Wanninger; Cheng Huang; Jeanon N Smith; Michael Patterson; Slobodan Paessler; Takaaki Koma
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

2.  Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Authors:  Joseph W Golden; Piet Maes; Steven A Kwilas; John Ballantyne; Jay W Hooper
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

3.  Monoclonal antibody therapy for Junin virus infection.

Authors:  Larry Zeitlin; Joan B Geisbert; Daniel J Deer; Karla A Fenton; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Andrew Hiatt; Michael H Pauly; Jesus Velasco; Kevin J Whaley; Friedrich Altmann; Clemens Gruber; Herta Steinkellner; Anna N Honko; Ana I Kuehne; M Javad Aman; Sara Sahandi; Sven Enterlein; Xiaoguo Zhan; Delia Enria; Thomas W Geisbert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

Review 4.  Pathogenesis and management of Kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman
Journal:  Expert Rev Anti Infect Ther       Date:  2010-02       Impact factor: 5.091

5.  Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus.

Authors:  Xiaoyan Pan; Yan Wu; Wei Wang; Leike Zhang; Gengfu Xiao
Journal:  Antiviral Res       Date:  2019-11-21       Impact factor: 5.970

Review 6.  Junín virus pathogenesis and virus replication.

Authors:  Ashley Grant; Alexey Seregin; Cheng Huang; Olga Kolokoltsova; Allan Brasier; Clarence Peters; Slobodan Paessler
Journal:  Viruses       Date:  2012-10-19       Impact factor: 5.048

7.  Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome.

Authors:  Chunyan Ye; Joseph Prescott; Robert Nofchissey; Diane Goade; Brian Hjelle
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

Review 8.  Animal models for Ebola and Marburg virus infections.

Authors:  Eri Nakayama; Masayuki Saijo
Journal:  Front Microbiol       Date:  2013-09-05       Impact factor: 5.640

Review 9.  Treatment of Argentine hemorrhagic fever.

Authors:  Delia A Enria; Ana M Briggiler; Zaida Sánchez
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

Review 10.  Searching for the cause of Kawasaki disease--cytoplasmic inclusion bodies provide new insight.

Authors:  Anne H Rowley; Susan C Baker; Jan M Orenstein; Stanford T Shulman
Journal:  Nat Rev Microbiol       Date:  2008-05       Impact factor: 60.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.